LUNALUST: THE NEXT GENERATION AI GIRLFRIEND APP

In an age where digital technology continuously reshapes our social interactions, LunaLust emerges as a groundbreaking application, setting new standards in the realm of virtual companionship. Today, LunaLust proudly announces the launch of its next-generation AI Girlfriend app, a platform designed to offer an unparalleled interactive experience. LunaLust’s AI Girlfriend app is not just a […]

Continue Reading

COMBATING VIRAL DISEASES WITH INNOVATIVE THERAPEUTIC APPROACHES

To combat and prevent pandemic infectious diseases more efficiently, the European Commission funds within the Horizon Europe Framework Programme a topic on “Pandemic preparedness and response: Broad spectrum anti-viral therapeutics for infectious diseases with epidemic potential” with a 50 million EUR budget. AVITHRAPID is a recently launched consortium under the EU’s Horizon research programme. The […]

Continue Reading

MINISTRY OF HEALTH IN THE KINGDOM OF SAUDI ARABIA, FAROUK, MAAMOUN TAMER & CO., AND OPEN MEDICAL PARTNER TO ADVANCE HEALTHCARE IN SAUDI ARABIA

Open Medical Europe, a leading provider of healthcare digital transformation solutions, is excited to announce a groundbreaking collaboration with the Ministry of Health (MOH) in the Kingdom of Saudi Arabia, and Farouk, Maamoun Tamer & Co. (Tamer) from Saudi Arabia. This strategic partnership is formalised through a Memorandum of Understanding (MOU), marking a significant stride […]

Continue Reading

REVOLUTIONIZING HEALTHCARE DIAGNOSTICS: FIRST AI BLOOD TEST RESULTS – INTERPRETATION SOFTWARE WITH EU-MDR CERTIFICATION

  Smart Blood Analytics Swiss, a pioneering leader in healthcare technology in the segment of blood test result interpretation, proudly announces that its groundbreaking product, SBAS Software, achieved the first EU-MDR (European Medical Device Regulation) certification1 as a medical device using cutting-edge AI technology for blood test result interpretation. Based on the European Database of […]

Continue Reading

WINTERMUTE BIOMEDICAL RECEIVES ETHICS APPROVAL FOR PHASE IB CLINICAL TRIAL OF SOLEXAN IN SHINGLES PATIENTS

Breaking Ground in Shingles Treatment: Wintermute Biomedical Advances to Clinical Trials … Wintermute Biomedical is excited to report that in December 2023 they have received full approval to conduct a Phase IB clinical trial in Australia using their first-in-class topical antiviral, Solexan. Solexan has been developed over the last 12 years by Wintermute Biomedical as a […]

Continue Reading